Shield Therapeutics plc
SHIEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $16 | $7 | $5 | $4 |
| % Growth | 108.4% | 56% | 34% | – |
| Cost of Goods Sold | $8 | $4 | $3 | $3 |
| Gross Profit | $8 | $4 | $2 | $1 |
| % Margin | 49.4% | 47.3% | 45% | 20.3% |
| R&D Expenses | $1 | $1 | $0 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11 | $6 | $7 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | $0 |
| Operating Expenses | $12 | $7 | $8 | $9 |
| Operating Income | -$4 | -$3 | -$6 | -$8 |
| % Margin | -27% | -44% | -115.9% | -226.1% |
| Other Income/Exp. Net | -$3 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$7 | -$4 | -$6 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$4 | -$6 | -$8 |
| % Margin | -44.5% | -58.4% | -127.6% | -236.4% |
| EPS | -0.007 | -0.006 | -0.008 | -0.011 |
| % Growth | -17.9% | 28.2% | 31.6% | – |
| EPS Diluted | -0.007 | -0.006 | -0.008 | -0.011 |
| Weighted Avg Shares Out | 1,042 | 784 | 782 | 742 |
| Weighted Avg Shares Out Dil | 1,042 | 783 | 782 | 742 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$3 | -$5 | -$8 |
| % Margin | -25.4% | -42.6% | -110.9% | -224.8% |